← DOOMRADAR

markets · Published brief

Novartis shares plunge after study on del-desiran drug

Novartis shares reportedly fell sharply after a study concerning the drug del-desiran. No size of the decline or study result is provided.

By DoomRadar · Published on DoomRadar .

Why it matters

A major clinical setback could affect a large pharmaceutical company and expectations for a potential treatment.

Related source links

These links were collected with this event. Recorded source dates may reflect when a link was found. Article publication dates are shown only when available from the source. Open the originals for their full context.

  1. Nach Studie zu Medikament Del-desiran: Novartis-Aktie stürzt ab ↗watson.ch · Recorded source date: Sep 8, 2026, 9:16 AM UTC

AI-assisted, source-based analysis. Methodology · Report a correction

Connected by topic or specific details. Dates below are publication dates; the articles may describe separate events.

MORE RECENT READING

Pharmaceutical company shares plunge after failed study

A major pharmaceutical company reportedly suffered a sharp share-price fall after a clinical study failed. The report indicates a material market reaction to disappointing trial results.

Related details in the reporting

MORE RECENT READING

Amgen shares fall after trial failure clouds cholesterol-drug prospects

Amgen shares fell 10% after a Novartis trial failure raised concerns about the cholesterol-drug class; Novartis shares reportedly fell 14%. The development affected major pharmaceutical companies and investor expectations.

Related details in the reporting

More in Markets & economy → · Browse the event archive →